Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
- DOI
- 10.1016/s2213-8587(26)00136-1
- Published
- 2026-10
- Container
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-26-00136-1,
title = {Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial},
author = {Linong Ji and Malik Benamar and Viswanathan Mohan and Laura Pletsch-Borba and Francesca Porcellati and Ni Wang and Hirotaka Watada and Rosangela R Rea},
year = {2026},
journal = {The Lancet Diabetes \& Endocrinology},
doi = {10.1016/s2213-8587(26)00136-1},
url = {https://doi.org/10.1016/s2213-8587(26)00136-1}
}RIS
TY - JOUR TI - Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial AU - Linong Ji AU - Malik Benamar AU - Viswanathan Mohan AU - Laura Pletsch-Borba AU - Francesca Porcellati AU - Ni Wang AU - Hirotaka Watada AU - Rosangela R Rea PY - 2026 JO - The Lancet Diabetes & Endocrinology DO - 10.1016/s2213-8587(26)00136-1 UR - https://doi.org/10.1016/s2213-8587(26)00136-1 ER -
APA
Ji, L., Benamar, M., Mohan, V., Pletsch-Borba, L., Porcellati, F., Wang, N., Watada, H., & Rea, R. R. (2026). Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(26)00136-1
Source records
- crossref · retrieved 2026-09-25T18:57:56.377Z